You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 18, 2024

~ Buy the VITRAKVI (larotrectinib sulfate) Drug Profile, 2024 PDF Report in the Report Store ~

VITRAKVI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


DrugPatentWatch® Generic Entry Outlook for Vitrakvi

Vitrakvi was eligible for patent challenges on November 26, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 15, 2036. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for VITRAKVI
International Patents:210
US Patents:18
Applicants:2
NDAs:2
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 91
Clinical Trials: 5
Patent Applications: 210
Drug Prices: Drug price information for VITRAKVI
What excipients (inactive ingredients) are in VITRAKVI?VITRAKVI excipients list
DailyMed Link:VITRAKVI at DailyMed
Drug patent expirations by year for VITRAKVI
Drug Prices for VITRAKVI

See drug prices for VITRAKVI

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for VITRAKVI
Generic Entry Dates for VITRAKVI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for VITRAKVI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VITRAKVI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
M.D. Anderson Cancer CenterPhase 2
Children's Oncology GroupPhase 2
PfizerPhase 2

See all VITRAKVI clinical trials

Pharmacology for VITRAKVI

US Patents and Regulatory Information for VITRAKVI

VITRAKVI is protected by nineteen US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VITRAKVI is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VITRAKVI

Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING NEUROBLASTOMA, GLIOMA, THYROID, AND BREAST CANCER SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

Methods of treating pediatric cancers
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING CMN, IFS, HGG, DIPGS, PTC, SOFT TISSUE SARCOMA, AND SPINDLE CELL SARCOMA SOLID TUMORS EXHIBITING AN NTRK GENE FUSION IN A PEDIATRIC PATIENT WITH AN ORAL SOLUTION

Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION AFTER SURGICAL RESECTION

Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyri- midin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING LUNG CANCER, UNDIFFERENTIATED SARCOMA, OR COLORECTAL CANCER THAT EXHIBITS AN NTRK GENE FUSION

Methods of treating pediatric cancers
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING CANCEROUS SOLID TUMORS

Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION

Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING CANCEROUS SOLID TUMORS

Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK GENE FUSION IN A PEDIATRIC PATIENT

Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyri- midin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: METHOD OF TREATING SOLID TUMORS THAT EXHIBIT AN NTRK FUSION GENE IN A PEDIATRIC PATIENT

FDA Regulatory Exclusivity protecting VITRAKVI

INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE NO SATISFACTORY ALTERNATIVE TREATMENTS OR THAT HAVE PROGRESSED FOLLOWING TREATMENT
Exclusivity Expiration: ⤷  Try a Trial

INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT HAVE A NEUROTROPHIC RECEPTOR TYROSINE KINASE (NTRK) GENE FUSION WITHOUT A KNOWN ACQUIRED RESISTANCE MUTATION
Exclusivity Expiration: ⤷  Try a Trial

INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH SOLID TUMORS THAT ARE METASTATIC OR WHERE SURGICAL RESECTION IS LIKELY TO RESULT IN SEVERE MORBIDITY
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bayer Healthcare VITRAKVI larotrectinib sulfate SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bayer Healthcare VITRAKVI larotrectinib sulfate SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bayer Healthcare VITRAKVI larotrectinib sulfate SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Bayer Healthcare VITRAKVI larotrectinib sulfate SOLUTION;ORAL 211710-001 Nov 26, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-002 Nov 26, 2018 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Bayer Hlthcare VITRAKVI larotrectinib sulfate CAPSULE;ORAL 210861-001 Nov 26, 2018 RX Yes No ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VITRAKVI

When does loss-of-exclusivity occur for VITRAKVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 8090
Estimated Expiration: ⤷  Try a Trial

Australia

Patent: 15346046
Estimated Expiration: ⤷  Try a Trial

Patent: 17246547
Estimated Expiration: ⤷  Try a Trial

Patent: 17246554
Estimated Expiration: ⤷  Try a Trial

Brazil

Patent: 2017010141
Estimated Expiration: ⤷  Try a Trial

Patent: 2018070017
Estimated Expiration: ⤷  Try a Trial

Patent: 2018070304
Estimated Expiration: ⤷  Try a Trial

Canada

Patent: 67951
Estimated Expiration: ⤷  Try a Trial

Patent: 19661
Estimated Expiration: ⤷  Try a Trial

Patent: 19671
Estimated Expiration: ⤷  Try a Trial

Chile

Patent: 17001249
Estimated Expiration: ⤷  Try a Trial

Patent: 18002806
Estimated Expiration: ⤷  Try a Trial

Patent: 18002807
Estimated Expiration: ⤷  Try a Trial

Patent: 19002238
Estimated Expiration: ⤷  Try a Trial

Patent: 19002239
Estimated Expiration: ⤷  Try a Trial

China

Patent: 7428760
Estimated Expiration: ⤷  Try a Trial

Patent: 9310694
Estimated Expiration: ⤷  Try a Trial

Patent: 9414442
Estimated Expiration: ⤷  Try a Trial

Patent: 3354649
Estimated Expiration: ⤷  Try a Trial

Colombia

Patent: 17005483
Estimated Expiration: ⤷  Try a Trial

Patent: 18010761
Estimated Expiration: ⤷  Try a Trial

Costa Rica

Patent: 170263
Estimated Expiration: ⤷  Try a Trial

Patent: 180501
Estimated Expiration: ⤷  Try a Trial

Croatia

Patent: 0230271
Estimated Expiration: ⤷  Try a Trial

Cuba

Patent: 180125
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 99181
Estimated Expiration: ⤷  Try a Trial

Dominican Republic

Patent: 018000214
Estimated Expiration: ⤷  Try a Trial

Ecuador

Patent: 18083443
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 18380
Estimated Expiration: ⤷  Try a Trial

Patent: 39662
Estimated Expiration: ⤷  Try a Trial

Patent: 39663
Estimated Expiration: ⤷  Try a Trial

Patent: 99181
Estimated Expiration: ⤷  Try a Trial

Finland

Patent: 99181
Estimated Expiration: ⤷  Try a Trial

Georgia, Republic of

Patent: 0227339
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 44483
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 61448
Estimated Expiration: ⤷  Try a Trial

Israel

Patent: 2270
Estimated Expiration: ⤷  Try a Trial

Patent: 2003
Estimated Expiration: ⤷  Try a Trial

Patent: 2005
Estimated Expiration: ⤷  Try a Trial

Patent: 0905
Estimated Expiration: ⤷  Try a Trial

Patent: 4018
Estimated Expiration: ⤷  Try a Trial

Japan

Patent: 14834
Estimated Expiration: ⤷  Try a Trial

Patent: 57343
Estimated Expiration: ⤷  Try a Trial

Patent: 61602
Estimated Expiration: ⤷  Try a Trial

Patent: 17535550
Estimated Expiration: ⤷  Try a Trial

Patent: 19510827
Estimated Expiration: ⤷  Try a Trial

Patent: 19511575
Estimated Expiration: ⤷  Try a Trial

Patent: 21169496
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 99181
Estimated Expiration: ⤷  Try a Trial

Mexico

Patent: 17006412
Estimated Expiration: ⤷  Try a Trial

Patent: 18012163
Estimated Expiration: ⤷  Try a Trial

Patent: 18012165
Estimated Expiration: ⤷  Try a Trial

Patent: 20011079
Estimated Expiration: ⤷  Try a Trial

Morocco

Patent: 601
Estimated Expiration: ⤷  Try a Trial

Patent: 610
Estimated Expiration: ⤷  Try a Trial

Patent: 612
Estimated Expiration: ⤷  Try a Trial

Patent: 504
Estimated Expiration: ⤷  Try a Trial

Nicaragua

Patent: 1800102
Estimated Expiration: ⤷  Try a Trial

Peru

Patent: 181888
Estimated Expiration: ⤷  Try a Trial

Philippines

Patent: 017500900
Estimated Expiration: ⤷  Try a Trial

Patent: 018502124
Estimated Expiration: ⤷  Try a Trial

Patent: 018502134
Estimated Expiration: ⤷  Try a Trial

Patent: 021550809
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 99181
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 99181
Estimated Expiration: ⤷  Try a Trial

Russian Federation

Patent: 23990
Estimated Expiration: ⤷  Try a Trial

Patent: 51636
Estimated Expiration: ⤷  Try a Trial

Patent: 51767
Estimated Expiration: ⤷  Try a Trial

Patent: 17120846
Estimated Expiration: ⤷  Try a Trial

Patent: 18137206
Estimated Expiration: ⤷  Try a Trial

Patent: 18138579
Estimated Expiration: ⤷  Try a Trial

Saudi Arabia

Patent: 8400168
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 122
Estimated Expiration: ⤷  Try a Trial

Singapore

Patent: 201703962X
Estimated Expiration: ⤷  Try a Trial

Patent: 201808559P
Estimated Expiration: ⤷  Try a Trial

Patent: 201808676R
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 99181
Estimated Expiration: ⤷  Try a Trial

South Africa

Patent: 1703501
Estimated Expiration: ⤷  Try a Trial

South Korea

Patent: 2400423
Estimated Expiration: ⤷  Try a Trial

Patent: 170082628
Estimated Expiration: ⤷  Try a Trial

Patent: 180128484
Estimated Expiration: ⤷  Try a Trial

Patent: 180129911
Estimated Expiration: ⤷  Try a Trial

Patent: 210010652
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 41630
Estimated Expiration: ⤷  Try a Trial

Taiwan

Patent: 46426
Estimated Expiration: ⤷  Try a Trial

Patent: 46537
Estimated Expiration: ⤷  Try a Trial

Patent: 67858
Estimated Expiration: ⤷  Try a Trial

Patent: 1625636
Estimated Expiration: ⤷  Try a Trial

Patent: 1801730
Estimated Expiration: ⤷  Try a Trial

Patent: 2206436
Estimated Expiration: ⤷  Try a Trial

Tunisia

Patent: 18000335
Estimated Expiration: ⤷  Try a Trial

Patent: 18000338
Estimated Expiration: ⤷  Try a Trial

Patent: 19000332
Estimated Expiration: ⤷  Try a Trial

Ukraine

Patent: 3044
Estimated Expiration: ⤷  Try a Trial

Patent: 5025
Estimated Expiration: ⤷  Try a Trial

Patent: 5026
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VITRAKVI around the world.

Country Patent Number Title Estimated Expiration
Hungary S2000006 ⤷  Try a Trial
Russian Federation 2018138579 СПОСОБЫ ЛЕЧЕНИЯ ДЕТСКИХ РАКОВЫХ ЗАБОЛЕВАНИЙ ⤷  Try a Trial
China 102264736 ⤷  Try a Trial
Ukraine 125026 РІДКІ КОМПОЗИЦІЇ (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)ПІРОЛІДИН-1-ІЛ)ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІДУ (LIQUID FORMULATIONS OF (S)-N-(5-(R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE) ⤷  Try a Trial
Russian Federation 2011120345 ЗАМЕЩЕННЫЕ ПИРАЗОЛО(1,5-a)ПИРАМИДИНОВЫЕ СОЕДИНЕНИЯ КАК ИНГИБИТОРЫ ТРК КИНАЗЫ ⤷  Try a Trial
Hungary E057625 ⤷  Try a Trial
Peru 20181888 FORMULACIONES LIQUIDAS DE (S)-N-(5-((R)-2-(2,5-DIFLUOROFENIL)-PIRROLIDIN-1-IL)-PIRAZOLO[1,5-A]PIRIMIDIN-3-IL)-3-HIDROXIPIRROLIDINA-1-CARBOXAMIDA ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VITRAKVI

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3106463 11/2020 Austria ⤷  Try a Trial PRODUCT NAME: LAROTRECTINIB UND/ODER PHARMAZEUTISCH AKZEPTABLE SALZE DAVON, INSBESONDERE LAROTRECTINIBSULFAT, EINSCHLIESSLICH LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190923
3106463 C202030011 Spain ⤷  Try a Trial PRODUCT NAME: LAROTRECTINIB Y/O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, PARTICULARMENTE SULFATO DE LAROTRECTINIB QUE INCLUYE HIDROGENOSULFATO DE LAROTRECTINIB; NATIONAL AUTHORISATION NUMBER: EU/1/19/1385; DATE OF AUTHORISATION: 20190919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1385; DATE OF FIRST AUTHORISATION IN EEA: 20190919
3106463 C03106463/01 Switzerland ⤷  Try a Trial PRODUCT NAME: LAROTRECTINIB; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67282 28.05.2020
3106463 122020000012 Germany ⤷  Try a Trial PRODUCT NAME: LAROTRECTINIB ODER ANDERE PHARMAZEUTISCH ANNEHMBARE SALZE DAVON, EINSCHLIESSLICH LAROTRECTINIBSULFATE UMFASSEND LAROTRECTINIBHYDROGENSULFAT; REGISTRATION NO/DATE: EU/1/19/1385 20190919
3106463 PA2020504,C3106463 Lithuania ⤷  Try a Trial PRODUCT NAME: LAROTREKTINIBAS IR (ARBA) FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, YPAC LAROTREKTINIBO SULFATAS, ISKAITANT LAROTREKTINIBO VANDENILIO SULFATA; REGISTRATION NO/DATE: EU/1/19/1385 20190919
3106463 722 Finland ⤷  Try a Trial
3106463 132020000000025 Italy ⤷  Try a Trial PRODUCT NAME: LAROTRECTINIB E/O SUOI SALI FARMACEUTICAMENTE ACCETTABILI, IN PARTICOLARE LAROTRECTINIB SOLFATO INCLUSO LAROTRECTINIB IDROGENO SOLFATO(VITRAKVI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1385, 20190923
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.